Uppsala Monitoring Centre

Day 4 | #ISoPCairo2025

🔹 #AI as a signal assessor
🔹 #MedSafetyWeek
🔹 Bengt Erik Wiholm Lecture

Day 3 | #ISoPCairo2025

🔹 Falsified and substandard medicines
🔹 ISoP General Assembly

Day 2 | #ISoPCairo2025

🔹 The future of #pharmacovigilance
🔹 The future of signal detection
🔹 Medical device and combination products
🔹 Pharmacogenomics and #DrugSafety
🔹 Updates from Latin America
🔹 Standardisation in #LatinAmerica

Day 1 | #ISoPCairo2025

🔹 Pre-conference course: #Pharmacovigilance in the community and #healthcare

⏱️ The countdown is on to #ISoP2025Cairo!

We will be on-site exhibiting, instructing, and presenting posters and sessions from 24–27 October in Cairo🇪🇬.

Explore the UMC agenda in the thread below👇 and visit the conference website for all details 🌐 isop2025cairo.org

YouTube video by Uppsala Monitoring Centre My Med Safety Story: Philippines

🎥 Since 2016, we've teamed up with pharmacovigilance stakeholders worldwide for #MedSafetyWeek. As we mark 10 years of the campaign, we wanted to know: 𝙬𝙝𝙖𝙩 𝙙𝙤𝙚𝙨 #𝙈𝙚𝙙𝙎𝙖𝙛𝙚𝙩𝙮𝙒𝙚𝙚𝙠 𝙢𝙚𝙖𝙣 𝙩𝙤 𝙩𝙝𝙚𝙢?

The Philippines share their story in the film below👇

Hot off the press – we celebrate 10 years of #MedSafetyWeek with a special joint issue of #UppsalaReports 🎉

This issue covers the evolution of the campaign, features inspiring success stories from partner countries, and innovative approaches to address underreporting.

👉 https://ow.ly/E29k50XeSei

ISoP Latin American chapter pushes forward medicines safety innovation More than 200 participants gathered in Mérida, Mexico, to discuss regional cooperation and emerging technologies in medicines safety across Latin America.

🌐 ISoP Latin American chapter pushes forward medicines safety innovation as over 200 participants gathered in Mérida🇲🇽 for the 7th Symposium.

Read up on how #LATAM is dxriving innovation and collaboration in #pharmacovigilance in the #UppsalaReports article below👇

Medicines can affect our personality in positive ways, but they may also lead to destructive behaviours. Listen to #DrugSafetyMatters with Michele Fusaroli to learn more about how to diagnose and treat drug-induced impulse control disorders. 
 
🎧 Tune in 👉 ow.ly/QMHR50RuLhn

👀 What was UMC up to in 2024?

Our Annual Report captures key operational highlights of the year and how we're working to serve the global #pharmacovigilance community for the better.

Dive inside to read about the Vigiverse, WHO PIDM updates, PV research, and more 👉https://ow.ly/mMmv50X7yTj

Strengthening healthcare systems against substandard medicines Counterfeit drugs threaten millions worldwide, yet healthcare workers often lack training to spot fakes or report them, leaving this problem largely invisible.

Substandard and falsified (SF) medicines threaten millions of people worldwide. Learn how investment in education, adoption of innovative technologies, and strengthening of pharmacovigilance systems can help address #FakeMeds in #UppsalaReports👇

Medication-related harm is especially prevalent in older adults due to changing physiology, increased frailty, and incidence of #polypharmacy.

Giovanni Furlan discusses #pharmacovigilance in older adults on the #DrugSafetyMatters podcast.

Listen now 🎧 ow.ly/vEeV50U67GU

#OlderPersonsDay

Exploring the Reliability of Detecting Drug–Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems - Drug Safety Background Adverse event reporting systems are an important source of safety signals for drug use in pregnancy, but their usefulness in the identification of potential drug–drug interactions (DDIs) remains unclear. Objective Our objective was to explore the reliability of signal detection for pharmacokinetic DDIs during pregnancy in adverse event reporting systems, focusing on potential interactions between antipsychotics (APs) or antidepressants (ADs) and drugs modifying cytochrome P450 (CYP450) activity, increasing the occurrence of gestational diabetes mellitus (GDM). Methods Reports related to the use of drugs during pregnancy were identified in VigiBase, the World Health Organization (WHO) global database of adverse event reports. Potential interacting drugs were selected based on WHO Drug Standardised Drug Groupings for CYP450 isoenzymes involved in the metabolic pathway of the AP or AD of interest. We conducted statistical interaction analysis using the omega disproportionality measure and including concomitant medication to identify potential DDIs, followed by a case series review for supporting evidence. Evaluation was subjective by author consensus. Results Of the 30 drug–drug–event combinations considered, statistical signals emerged for escitalopram, citalopram, and sertraline and the simultaneous use of CYP2D6 inhibitors with a higher relative reporting rate of GDM. However, case series review of reports did not support the existence of these DDIs because of uncertainties regarding the actual timing of medication use reported as concomitant. Conclusion Statistical signals of DDIs between ADs and potential interacting drugs during pregnancy were identified but not pursued further after case reviews. Uncertainty around medication use and event timing affected the reliability of the outcomes. These findings highlight the need to validate signals using detailed report data and stress the importance of accurate medication reporting.

📖 A new article featuring contributions from UMC and led by colleagues at Lareb, explores signal detection for pharmacokinetic DDIs during pregnancy that increase the occurrence of gestational diabetes mellitus.

#OpenAccess at the link below👇

📆 Just under 1 month to go until #ISoPCairo2025!

From pre-conference training courses to panel discussions & interactive sessions, this year's ISoP Annual Meeting will take us back to the future of #pharmacovigilance.

Key event details in the flyer below👇 & online 🌐 https://isop2025cairo.org/

VigiMobile Launches in Oman: A Digital Step Forward in Pharmacovigilance Oman’s VigiMobile launch is more than a technical upgrade. It signals a strong commitment to patient safety and public participation in pharmacovigilance.

Oman🇴🇲 takes a digital step forward in #pharmacovigilance, joining the growing network of #VigiMobile users.

Read #UppsalaReports to learn how they're helping to lower reporting barriers with the help of the mobile reporting tool, making the reporting process accessible and intuitive👇

On #WorldPharmacistsDay, we're looking back to #MedSafetyWeek 2023 👀

Pharmacists play a vital role the cycle of medicines safety. They are the first point of contact for patients and carers when they have questions about their medicines, including how to prevent or manage side effects.

#WPD2025

Our beginner's guide to #pharmacovigilance covers the ABCs of PV, including:

🔹 What adverse reactions are
🔹 Preventing medication errors
🔹 National and global reporting systems
... and much more

Download your copy here 👉 ow.ly/l5jQ50WXA6x

👦🏽 Administration errors

Errors can happen when giving medicine, such as when a liquid dose isn’t measured accurately or when a child doesn’t receive the full amount.

👧🏼 Dispensing challenges

Medications prescribed for children often require precise calculations based on age, size, and weight, increasing the risk of dosing errors.

🧒🏻 Lack of paediatric guidelines

Many medications do not have specific dosing guidelines for children, making it difficult to determine the correct dose.

This year's #PatientSafetyDay called for action to prevent avoidable harm in paediatric care.

Learn more about the factors impacting child patients in the thread below👇 and read our #DeepDive for more on #MedicationErrors 👉 ow.ly/F4q150W5qYF

The 2018 #MedSafetyWeek campaign highlighted medicines safety for children. What should we keep in mind to help make medicines safer?

➡️ Make sure the medicine is right for the baby or child
➡️ Give the right medicine in the right dose, using the right spoon, syringe or device
➡️ Report side effects

Today is #WorldPatientSafetyDay, & we're joining the campaign for safe care for every newborn and child.

Newborns & children are some of the most vulnerable patients, requiring special care in all healthcare settings.

Let's help ensure #PatientSafety from the start. Learn how 👉 ow.ly/qI5a50WXX6h

Rethinking Medical Device Safety in a Drug-Centric World From software updates to complex human-machine interactions, medical devices pose safety challenges that require dedicated frameworks beyond drug vigilance.

Medical device safety is not simply #pharmacovigilance 2.0.

From complex human-machine interactions to software updates, #MedicalDevices post safety challenges that require dedicated frameworks beyond drug vigilance.

Read #UppsalaReports for more👇

Join #CIOMS for a webinar that introduces and explains the main concepts of the CIOMS report on Benefit-risk balance for medicinal products:

📆 Wednesday, 10 September 2025
🕑 14:00 CEST
🌐 Online

Register to attend via the link below👇

👦🏾👧🏻 Ahead of #WPSD2025 on 17 September, we spoke with
Angela Caro-Rojas to discuss the challenges and solutions in paediatric #pharmacovigilance and how we can put children first when it comes to #PatientSafety.

🎧 Listen to #DrugSafetyMatters for more 👉 ow.ly/8Gfp50WPCSl

Event flyer with text that reads: The GIDWG Stakeholder Public Meeting, streaming via Zoom, 3 October 2025, 12:30 – 14:00 CEST.

📣 Join us for the GIDWG Stakeholder Public Meeting!

UMC, on behalf of the Global #IDMP Working Group (GIDWG), is pleased to invite you to an online public meeting, streaming live from the @ema.europa.eu:

📆 Friday, 3 October 2025
🕛 12:30 – 14:00 CEST
📍 Online via Zoom

Register 👉 ow.ly/mau350WMFvM

How diclofenac drove vultures to the brink and unleashed a rabies crisis How one unusual crisis highlights the need to more effectively integrate the One Health approach and ecopharmacovigilance into pharmaceutical monitoring and legislation.

From the collapse of vulture populations to a public health crisis, the veterinary use of #diclofenac highlights the need to integrate #OneHealth and #ecopharmacovigilance into pharmaceutical monitoring and legislation.

Read more in #UppsalaReports at the link below👇

Our collection of #eLearning courses cover different aspects of #pharmacovigilance, with the aim to support WHO PIDM members and other organisations using UMC's products.

The latest course equips learners with a pharmacovigilance #communications toolbox 🧰

Learn more 👉 ow.ly/f1TX50WMQ5g

Advancing Global Harmonization: Implementing Global Dose Form Attributes for Medicinal Products Identification - Therapeutic Innovation & Regulatory Science The global pharmaceutical market includes a wide range of medicinal products, which makes it difficult to achieve consistent identification and classification across different regions. To address this...

Researchers affiliated with the Global #IDMP Working Group, including UMC staff, investigate the feasibility of assigning global dose form attributes to standardise and improve global data harmonisation.

Read the #OpenAccess article at the link below👇